Want to see TFX full AI Analyst Report?
TFX Stock Chart & Stats
$132.10
$0.94(0.72%)
At close: 4:00 PM EDT
$132.10
$0.94(0.72%)
Day’s Range― - ―
52-Week Range$100.18 - $145.00
Previous CloseN/A
Volume514.54K
Average Volume (3M)423.26K
Market Cap
$5.72B
Enterprise Value$8.09K
Total Cash (Recent Filing)$300.16M
Total Debt (Recent Filing)$2.87B
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Oct 22, 2026EPS Estimate
1.9Next Dividend Ex-DateN/A
Dividend Yield0.98%
Share Statistics
EPS (TTM)-23.28
Shares Outstanding42,372,400
10 Day Avg. Volume405,055
30 Day Avg. Volume423,264
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.74
Price to Sales (P/S)2.73
P/FCF Ratio22.19
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$156.25Price Target Upside18.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)7.14
Revenue Forecast (FY)$2.27B
Bulls Say, Bears Say
Bulls Say
Recurring Procedure-driven DemandTeleflex’s consumables-oriented model links demand to recurring hospital procedures and product replacement. This supports revenue durability and customer retention, although growth still depends on procedure volumes, product adoption and hospital purchasing decisions.
Core Segment Growth And InnovationGrowth in vascular and surgical franchises, combined with EZPLAZ approval and Freesolve milestones, strengthens Teleflex’s specialty portfolio. New clinically differentiated products can expand adoption, support mix and reinforce its position in critical-care markets.
Portfolio Focus And Debt ReductionExiting OEM sharpens focus on core medical technology franchises while releasing capital for debt repayment. Lower leverage can reduce interest costs and improve strategic flexibility, allowing greater investment in higher-priority products and commercial execution.
Bears Say
Severely Weakened ProfitabilityThe sharp shift from historical profitability to substantial losses is the most material fundamental risk. Persistent margin pressure, charges or unfavorable mix could impair reinvestment capacity and make earnings recovery dependent on successful restructuring and execution.
Integration And Growth Execution RiskDelayed order-to-cash, distributor and sales-force integration indicates execution complexity in a strategically important segment. If disruptions persist through 2026, they may constrain organic growth, dilute customer relationships and delay expected benefits from the acquisition.
Higher Leverage And Weaker Cash CoverageLeverage has increased materially while cash-flow coverage has weakened versus prior years. Although debt repayment improves the trajectory, the combination of negative earnings and lower liquidity coverage limits financial flexibility if operating recovery or divestiture timing falls short.
Teleflex News
TFX FAQ
What was Teleflex’s price range in the past 12 months?
Teleflex lowest stock price was $100.18 and its highest was $145.00 in the past 12 months.
What is Teleflex’s market cap?
Teleflex’s market cap is $5.72B.
When is Teleflex’s upcoming earnings report date?
Teleflex’s upcoming earnings report date is Oct 22, 2026 which is in 60 days.
How were Teleflex’s earnings last quarter?
Teleflex released its earnings results on Aug 06, 2026. The company reported $1.76 earnings per share for the quarter, beating the consensus estimate of $1.281 by $0.479.
Is Teleflex overvalued?
According to Wall Street analysts Teleflex’s price is currently Undervalued.
Does Teleflex pay dividends?
Teleflex pays a Quarterly dividend of $0.34 which represents an annual dividend yield of 0.98%. See more information on Teleflex dividends here
What is Teleflex’s EPS estimate?
Teleflex’s EPS estimate is 1.9.
How many shares outstanding does Teleflex have?
Teleflex has 42,372,400 shares outstanding.
What happened to Teleflex’s price movement after its last earnings report?
Teleflex reported an EPS of $1.76 in its last earnings report, beating expectations of $1.281. Following the earnings report the stock price went up 1.543%.
Which hedge fund is a major shareholder of Teleflex?
Currently, no hedge funds are holding shares in TFX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Teleflex Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$156.25 (18.28% Upside)
$156.25 (18.28% Upside)
Blogger Sentiment
Bullish
TFX Sentiment 67%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 647.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.7%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.98%
12-Months-Change
Fundamentals
Return on Equity
0.98%
Trailing 12-Months
Asset Growth
-7.98%
Trailing 12-Months
Company Description
Teleflex
Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex's interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spirometry equipment, and ventilation management systems, applicable across diverse healthcare settings. Teleflex serves a broad customer base, encompassing hospitals, healthcare providers, medical device manufacturers, and the home care market. Established in 1943, the company maintains its headquarters in Wayne, Pennsylvania.
TFX Company Deck
TFX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a cautiously optimistic outlook: management reported a quarter that beat on revenue, margin and EPS expectations, closed a sizable OEM divestiture generating ~$1.5B of proceeds to accelerate debt paydown and share repurchases, and highlighted meaningful innovation and R&D progress (EZPLAZ approval, Freesolve milestones). However, the company is navigating near-term headwinds — primarily slower-than-expected integration of the VI acquisition that pressured Interventional revenue, margin compression from tariffs and acquisition mix, stranded costs and regulatory timing on remaining divestitures. Management reiterated a clear plan to reduce debt, return capital, increase R&D focus and deliver margin improvement in 2027, and raised FY EPS guidance while trimming FY revenue growth guidance. On balance, the positive strategic moves, capital returns and innovation progress outweigh the transient integration and margin challenges, with improved financial profile expected in 2027.View all TFX earnings summariesTFX Stock 12 Month Forecast
Average Price Target
$156.25
▲(18.28% Upside)
Technical Analysis
Haemonetics
―
ICU Medical
―
Lemaitre Vascular
―
Merit Medical Systems
―
Bausch + Lomb Corporation
―
Ownership Overview
0.44% Insiders
36.72% Mutual Funds
17.01% Other Institutional Investors
22.26% Public Companies and
Individual Investors